

Christelle FerrÃ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9370056/publications.pdf>

Version: 2024-02-01

66
papers

2,200
citations

257450
24
h-index

223800
46
g-index

76
all docs

76
docs citations

76
times ranked

3434
citing authors

#	ARTICLE	IF	CITATIONS
1	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2016, 374, 43-53.	27.0	436
2	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. Journal of Clinical Oncology, 2008, 26, 577-584.	1.6	213
3	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	7.6	128
4	Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 4578-4584.	1.6	116
5	Changes in critically ill cancer patients's short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. Intensive Care Medicine, 2019, 45, 977-987.	8.2	100
6	Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leukemia and Lymphoma, 2008, 49, 1752-1761.	1.3	98
7	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	1.4	68
8	Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 701-706.	2.0	59
9	Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. International Journal of Hematology, 2007, 85, 195-202.	1.6	59
10	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplantation, 2020, 55, 641-648.	2.4	58
11	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood, 2013, 122, 3951-3959.	1.4	55
12	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization.. Cytotherapy, 2012, 14, 823-829.	0.7	50
13	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology, 2019, 6, e89-e99.	4.6	47
14	Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study. Biology of Blood and Marrow Transplantation, 2009, 15, 639-642.	2.0	45
15	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. Biology of Blood and Marrow Transplantation, 2016, 22, 584-588.	2.0	45
16	Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM</i> FISH deletions. Oncotarget, 2017, 8, 54297-54303.	1.8	44
17	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. British Journal of Haematology, 2012, 157, 67-74.	2.5	39
18	Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. Biology of Blood and Marrow Transplantation, 2017, 23, 491-497.	2.0	37

#	ARTICLE	IF	CITATIONS
19	Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. <i>Critical Care</i> , 2018, 22, 326.	5.8	37
20	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
21	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 957-966.	2.0	35
22	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 2432-2444.	2.4	33
23	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 656-662.	1.3	32
24	Positive selection for CD34 + reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2003, 31, 545-550.	0.4	31
25	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. <i>Annals of Hematology</i> , 2021, 100, 541-553.	1.8	25
26	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1387-1392.	2.0	24
27	Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. <i>European Journal of Haematology</i> , 2014, 93, 487-491.	2.2	23
28	Post-Thaw Viable CD45 + Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2167-2172.	2.0	17
29	Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. <i>Expert Review of Hematology</i> , 2011, 4, 9-16.	2.2	16
30	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 378-384.	3.5	16
31	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. <i>Experimental Hematology</i> , 2018, 62, 24-32.	0.4	15
32	Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2489-2496.	2.4	15
33	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. <i>Cytotherapy</i> , 2014, 16, 406-411.	0.7	13
34	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1919-1928.	2.4	13
35	Cord Blood Units with High CD3 + Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1073-1079.	2.0	11
36	A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy. <i>Journal of Neuro-Oncology</i> , 2002, 59, 35-38.	2.9	9

#	ARTICLE	IF	CITATIONS
37	FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 421-428.	1.5	9
38	Few and Nonsevere Adverse Infusion Events Using an Automated Method for Diluting and Washing before Unrelated Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 682-687.	2.0	7
39	Autologous stem cell transplantation and purging in adult acute lymphoblastic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 675-693.	1.7	6
40	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	5.2	6
41	Antithymocyte globulin therapy for steroidâ€resistant acute graft versus host disease. <i>American Journal of Hematology</i> , 2008, 83, 824-825.	4.1	5
42	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 916-922.	1.3	5
43	Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. <i>Bone Marrow Transplantation</i> , 2022, 57, 1531-1538.	2.4	5
44	Long-Term disease-free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN-Î±. <i>American Journal of Hematology</i> , 2002, 71, 62-62.	4.1	4
45	Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back. <i>European Journal of Haematology</i> , 2004, 73, 162-168.	2.2	4
46	Outcome and Toxicity of Salvage Treatment in Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation--Experience from a Single Center. <i>Hematology</i> , 2003, 8, 145-150.	1.5	3
47	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. <i>Leukemia Research</i> , 2017, 58, 98-101.	0.8	3
48	Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 992-996.	2.4	3
49	A case of non-lethal pulmonary air embolism after leukapheresis catheter removal. <i>Journal of Clinical Apheresis</i> , 2005, 20, 93-94.	1.3	2
50	Estudio prospectivo del seguimiento de pacientes largos supervivientes a un trasplante alogÃ©nico de progenitores hematopoyÃ©ticos. <i>Medicina ClÃnica</i> , 2021, 157, 281-284.	0.6	2
51	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. <i>Leukemia and Lymphoma</i> , 0, , 425-430.	1.3	2
52	Post thawing viable CD34+â€Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	2
53	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1173-1175.	1.3	1
54	5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S270-S272.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. American Journal of Hematology, 2017, 92, E132-E135.	4.1	1
56	Impact of previous admission to an intensive care unit on stem cell transplantation outcome. Medicina Clínica, 2020, 155, 382-387.	0.6	1
57	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis. Oncology and Therapy, 2020, 8, 311-324.	2.6	1
58	Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. Medicina Clínica, 2021, , .	0.6	1
59	Gemtuzumab ozogamicina a bajas dosis en adultos con leucemia mieloide aguda. Medicina Clínica, 2021, 157, 325-328.	0.6	1
60	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplantation, 0, , .	2.4	1
61	Utilidad del lavado broncoalveolar y la citometría de flujo en pacientes con hemopatías malignas e insuficiencia respiratoria. Medicina Clínica, 2017, 148, 297-302.	0.6	0
62	Tratamiento de rescate de pacientes con leucemia aguda en recaída después de un primer trasplante alogénico de progenitores hematopoyéticos. Medicina Clínica, 2018, 151, 376-377.	0.6	0
63	Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. Medicina Clínica, 2018, 150, 421-427.	0.6	0
64	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1133-1137.	2.4	0
65	Enfermedad del injerto contra el receptor tras infección por Rickettsia conorii inducida por la picadura de una garrapata. Medicina Clínica, 2019, 152, 119-120.	0.6	0
66	Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. Blood, 2016, 128, 3484-3484.	1.4	0